RGEN Stock Analysis: Buy, Sell, or Hold?
RGEN - Repligen Corp
$144.88
0.64 (0.44%)
▲
5d:
+2.42%
30d:
+10.8%
90d:
+20.63%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
21d
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RGEN shows positive signals but monitor for confirmation. Market pricing in 1.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: RGEN shows positive signals but monitor for confirmation. Market pricing in 1.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$124.03
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$77.01
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $144.88, which is considered extended relative to its 30-day fair value range of $128.37 to $142.20. The stock's valuation (Forward PE: 56.6) is in line with its historical norms (58.8). Remarkably, the market is currently pricing in an annual earnings decline of 1.3% over the next few years. This pessimistic expectation contrasts with the company's recent 47.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, RGEN is in a strong downtrend. The price is approaching resistance at $132.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RGEN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $177.05 (+22.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RGEN is in a strong downtrend. The price is approaching resistance at $132.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RGEN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $177.05 (+22.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$128.37 -
$142.20
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.7% below Wall St target ($177.05)
Trading Range Analysis
30-Day Trading Range
$128.37 -
$142.20
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$112.00
Resistance Level
$132.25
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
56.62
Wall Street Target
$177.05
(+22.7%)
Revenue Growth (YoY)
14.8%
Earnings Growth (YoY)
47.9%
Profit Margin
6.7%
Valuation Discount vs History
-1.3% cheaper
PE vs Historical
56.6 vs 58.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.3%
(market-implied from PE analysis)
1-Year Target
$142.36
(-1%)
2-Year Target
$140.51
(-3%)
3-Year Target
$138.69
(-4%)
3-Yr Target (if PE normalizes)
(PE: 57→59)
$144.03
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 56.6, Growth: 27.2%)
$297.09
(+106%)
Base:
(SPY PE: 21.8, Growth: 27.2%)
$114.29
(-21%)
Bear:
(PE: 18.5, Growth: 27.2%)
$97.14
(-33%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (69x PE), but valuation improves significantly next year (57x PE) as earnings recover.
Forward PE: 69.44 | Forward EPS (Implied): $2.08
Bull Case
$174.17
(+21%)
Analyst growth 15.0%, PE expands to 72.9
Base Case
$144.24
(0%)
Market implied 0.0%, PE stable at 69.4
Bear Case
$110.34
(-24%)
Severe decline -15.0%, PE contracts to 62.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 56.6 to 58.8
Stabilization Target:
$149.80
(+3.9%)
PE Expansion Potential:
+3.9%
Share & Embed Analysis
Last updated: July 13, 2026 4:21 PM ET
Data refreshes hourly during market hours. Next update: 5:21 PM
Data refreshes hourly during market hours. Next update: 5:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$562 | 63 BUY |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$88 | 61 BUY |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$366 | 63 BUY |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$81 | 61 BUY |
|
ALGN
Align Technology Inc |
BUY
18 analysts |
$209 | 61 BUY |
